Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News HUTCHMED (China) Ord Shs HMDCF

Healthcare Biotechnology
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (OTCPK:HMDCF)

Initiation of Sulfatinib Phase III Registration Study in Neuroendocrine Tumor Patients

PR Newswire December 18, 2015

US$105 Million Shanghai Land Compensation Agreement

PR Newswire December 9, 2015

Initiation of Fruquintinib Phase III Registration Trial in Non-small Cell Lung Cancer

PR Newswire December 8, 2015

Chi-Med Initiates Sulfatinib U.S. Clinical Trials

PR Newswire November 6, 2015

Completion of Phase I Clinical Trial of Novel Syk Inhibitor HMPL-523 for Autoimmune Diseases in Healthy Volunteers

PR Newswire October 30, 2015

Sulfatinib Clinical Results and Fruquintinib-Savolitinib Combination Preclinical Results to be Presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

PR Newswire October 30, 2015

Proof-of-concept Study of Fruquintinib in Non-small Cell Lung Cancer Triggers Milestone Payment

PR Newswire October 23, 2015

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing

PR Newswire October 16, 2015

Savolitinib Completes Enrolment for Phase II Clinical Trial in Papillary Renal Cell Carcinoma

PR Newswire October 13, 2015
View More News ››

Opinion & Analysis (OTCPK:HMDCF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (OTCPK:HMDCF)

Be the first to post on this bullboard.

Fiddlehead Resources Corp.

Fiddlehead Resources Corp.

Fiddlehead Resources Corp. is a TSXV listed Cardium-focused oil and gas producer with 1,750 boepd of low decline, high ...
View More »